Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

RxSight (RXST) EBT (2020 - 2026)

RxSight filings provide 6 years of EBT readings, the most recent being -$9.1 million for Q4 2025.

  • On a quarterly basis, EBT fell 142.58% to -$9.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$38.9 million, a 3888000.0% decrease, with the full-year FY2025 number at -$38.9 million, down 3887900.0% from a year prior.
  • EBT hit -$9.1 million in Q4 2025 for RxSight, up from -$9.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $33.0 million in Q4 2021 to a low of -$17.6 million in Q1 2022.
  • Median EBT over the past 5 years was -$10.8 million (2025), compared with a mean of -$7.7 million.
  • Biggest five-year swings in EBT: plummeted 158.78% in 2022 and later skyrocketed 333.55% in 2024.
  • RxSight's EBT stood at $33.0 million in 2021, then plummeted by 147.34% to -$15.6 million in 2022, then surged by 41.06% to -$9.2 million in 2023, then skyrocketed by 333.55% to $21.5 million in 2024, then tumbled by 142.58% to -$9.1 million in 2025.
  • The last three reported values for EBT were -$9.1 million (Q4 2025), -$9.8 million (Q3 2025), and -$11.8 million (Q2 2025) per Business Quant data.